TABLE 16Definitions of CHR in high-dose imatinib studies

StudyDefinition
Breccia et al. (2010)9WBC count < 10 × 109/l with no immature cells in the peripheral blood

Platelet count < 450 × 109/l

Disappearance of all signs and symptoms related to leukaemia
Kantarjian et al. (2007),6 (2009)7WBCs ≤ institutional ULN

Platelets < 450 × 109/l

No blasts or promyelocytes in peripheral blood

< 5% myelocytes plus metamyelocytes in peripheral blood

No extramedullary involvement (including no hepatomegaly or splenomegaly)
Rajappa et al. (2010)8Not reported

ULN, upper limit of normal; WBC, white blood cell.

From: 3, Clinical effectiveness

Cover of Dasatinib, High-Dose Imatinib and Nilotinib for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation
Dasatinib, High-Dose Imatinib and Nilotinib for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 16.23.
Loveman E, Cooper K, Bryant J, et al.
Southampton (UK): NIHR Journals Library; 2012 May.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.